MYELODYSPLASTIC SYNDROMES (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROMES (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 19:34 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goa…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New targeted pill takes on chemotherapy in rare bone marrow cancer trial
Disease control Recruiting nowThis study tests two different drugs in adults with a rare type of bone marrow cancer called myelodysplastic syndromes (MDS) that has a specific genetic change (IDH1 mutation). Participants have not received a common first treatment (HMA) before. They will be randomly assigned to…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 22, 2026 12:00 UTC
-
New drug cocktail aims to tame deadly transplant side effect
Disease control Recruiting nowThis phase 2 trial tests whether adding two drugs, ruxolitinib and abatacept, to standard transplant care can prevent graft-versus-host disease (GVHD) in 60 patients with high-risk myeloid cancers like AML and MDS. Participants receive a stem cell transplant from a partially matc…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New cord blood transplant method could boost survival in tough blood cancers
Disease control Recruiting nowThis study is testing an improved method for cord blood transplants in adults with high-risk blood cancers like leukemia and lymphoma. The goal is to see if this optimized approach helps more people survive and recover with fewer side effects. About 54 participants will receive t…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New drug could help High-Risk patients get Life-Saving transplants
Disease control Recruiting nowThis early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New hope for leukemia patients? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Blood disorder drug luspatercept under Long-Term safety review
Disease control Recruiting nowThis study looks at the long-term safety of luspatercept in people with certain blood disorders (MDS, beta-thalassemia, or myelofibrosis) who were in earlier luspatercept trials. Participants either continue treatment or enter long-term follow-up to monitor side effects, disease …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC